Related Experiment Video

Updated: Aug 18, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation

Jorik R Timmer1, Jan Paul Ottervanger, Menko-Jan de Boer

  • 1Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, the Netherlands.

Journal of the American College of Cardiology
|April 6, 2005
PubMed

Insights

Elevated glucose levels, or hyperglycemia, in ST-segment elevation myocardial infarction (STEMI) patients are linked to poorer Thrombolysis In Myocardial Infarction (TIMI) flow before primary percutaneous coronary intervention (PCI). This indicates hyperglycemia impairs coronary blood flow before treatment.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Metabolic Syndrome

Background:

  • Reperfusion prior to primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients improves outcomes.
  • Hyperglycemia in STEMI patients correlates with a worse prognosis.
  • Hyperglycemia may promote a pro-thrombotic state, potentially affecting Thrombolysis In Myocardial Infarction (TIMI) flow before PCI.

Purpose of the Study:

  • To determine if elevated glucose levels are associated with impaired TIMI flow before primary PCI.
  • To assess the impact of hyperglycemia on coronary blood flow in STEMI patients undergoing primary PCI.

Main Methods:

  • Analysis of 460 consecutive STEMI patients undergoing primary PCI.
  • Hyperglycemia defined as glucose ≥7.8 mmol/l (140 mg/dl).
  • Evaluation of TIMI flow grade before primary PCI.

Main Results:

  • Hyperglycemia was present in 70% of patients; TIMI flow grade 3 was observed in 17%.
  • Patients with hyperglycemia had significantly less frequent TIMI grade 3 flow (12% vs. 28%, p < 0.001).
  • Hyperglycemia strongly predicted the absence of reperfusion before primary PCI (OR 2.6; 95% CI 1.5-4.5) after adjustments.

Conclusions:

  • Hyperglycemia in STEMI patients is a significant predictor of impaired epicardial flow before reperfusion therapy.
  • Further research is needed to explore interventions that enhance coronary flow before primary PCI in hyperglycemic STEMI patients.
Abstract

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...